Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Enterprise Value (2016 - 2025)

RedHill Biopharma has reported Enterprise Value over the past 15 years, most recently at -$4.0 million for Q4 2025.

  • Quarterly Enterprise Value rose 34.23% to -$4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.0 million through Dec 2025, up 34.23% year-over-year, with the annual reading at -$4.0 million for FY2025, 34.23% up from the prior year.
  • Enterprise Value was -$4.0 million for Q4 2025 at RedHill Biopharma, up from -$4.6 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$4.0 million in Q4 2025 and troughed at -$76.0 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$22.6 million (2022), against an average of -$28.3 million.
  • Year-over-year, Enterprise Value plummeted 115.69% in 2021 and then skyrocketed 72.07% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$29.5 million in 2021, then grew by 23.35% to -$22.6 million in 2022, then skyrocketed by 72.07% to -$6.3 million in 2023, then grew by 4.31% to -$6.0 million in 2024, then skyrocketed by 34.23% to -$4.0 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Enterprise Value are -$4.0 million (Q4 2025), -$4.6 million (Q2 2025), and -$6.0 million (Q4 2024).